Drug Profile
Breceptin
Alternative Names: B201; B201-acetateLatest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator ApopLogic Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants; Bradykinin B1 receptor antagonists; Bradykinin B2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Non-small cell lung cancer; Prostate cancer
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
- 28 Aug 2018 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 29 Aug 2016 Preclinical development is underway for Solid tumours in USA.